Ironwood Pharmaceuticals, Inc.
(NASDAQ : IRWD)

( )
IRWD PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
SAVACassava Sciences, Inc. 1.17%53.480.0%$625.89m
CTLTCatalent, Inc. -0.08%135.982.0%$167.28m
VRXValeant Pharmaceuticals International, Inc. 0.00%28.2114.1%$165.99m
PRGOPerrigo Co. Plc 0.68%43.036.9%$139.81m
ICLRICON plc 0.00%269.962.8%$115.50m
HZNPHorizon Therapeutics Plc 0.00%109.765.5%$105.41m
JAZZJazz Pharmaceuticals Plc 0.00%129.102.1%$95.77m
INDPIndaptus Therapeutics, Inc. 0.85%8.340.0%$93.78m
ARGXargenx SE -1.37%312.050.0%$67.41m
BHCBausch Health Cos., Inc. 0.00%28.210.0%$57.35m
AXSMAxsome Therapeutics, Inc. 2.34%31.941.8%$55.32m
UTHRUnited Therapeutics Corp. 0.00%198.8314.0%$49.03m
ENDPEndo International Plc -0.36%2.758.5%$48.70m
SAGESAGE Therapeutics, Inc. 0.00%45.237.6%$21.01m
IRWDIronwood Pharmaceuticals, Inc. 0.00%12.679.5%$20.95m

Company Profile

Ironwood Pharmaceuticals, Inc. is a healthcare company, which focuses on the development and commercialization of Gastrointestinal (GI) product opportunities in areas of significant unmet need, leveraging demonstrated expertise and capabilities in GI diseases. Its products include linaclotide, a guanylate cyclase type-C agonists which treats patients irritable bowel syndrome with constipation and chronic constipation. The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook Jr., and Gina Bornino Miller on January 5, 1998 and is headquartered in Boston, MA.